A publicly-traded biopharmaceutical company, which had just emerged out of bankruptcy protection, retained CRA to conduct its intangible asset and goodwill impairment testing. First, CRA performed a ASC 360 recoverability test of the company’s intangible asset group, which included distribution agreements, customer relationships, non-compete agreements, and trade name. CRA then conducted a ASC 350 goodwill impairment analysis, which included both a comparison of the company’s carrying value with its fair value as well as a hypothetical purchase price allocation, to determine the goodwill impairment loss.
IP Literature Watch: June 2025
We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on antitrust & IP, licensing, litigation, innovation, law...